Values and Preferences. Pneumonia Update Key Topics to Cover
|
|
- Sharleen McCarthy
- 6 years ago
- Views:
Transcription
1 Pneumonia Update 2016 Management of the Hospitalized Patient October, 2016 Scott A. Flanders, M.D., MHM Professor of Medicine Director, Hospital Medicine Program Associate Chair for Quality and Innovation University of Michigan Disclosure of Financial Relationships Scott A. Flanders, MD Has disclosed relationships with entities producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Consultant NONE Research and Grant Support CDC Foundation AHRQ Blue Cross Blue Shield, MI Pneumonia Guideline Groups * ATS / IDSA GL panel member Advisory Boards NONE Speakers Bureau NONE Board Member NONE * non-financial Key Topics to Cover Values and Preferences Pneumonia Diagnosis: CXR / Etiologies / Procalcitonin Antibiotics Steroids Healthcare-Associated Pneumonia Which pneumonia patients are at risk for resistant organisms? 1. Recommend treatments shown to improve clinical outcomes 2. Reduce unnecessary antibiotic use -Use lowest number / spectrum of antibiotics -De-escalate rapidly and shorten durations 1
2 A National Priority First attempt to characterize the annual human toll of antibiotic resistance. Clostridium difficile diagnoses: U.S. Hospitals Lessa, et al. NEJM ,000 US cases (2011) 66% healthcare associated 29,000 deaths Current Challenges Conditions Driving Antibiotic Use Antibiotic Use in U.S. Hospitals The Big Three CDC: trend analysis over 550 hospitals; % of patients on antibiotics Overall use stable; shift to more broad spectrum use Baggs, J, et al., JAMA IM, %-50% of use is felt to be inappropriate Dellit TH, Clin Infect Dis Fridkin S, MMWR, 2014 #1 Urinary Tract Infection (UTI) #2 Pneumonia #3 Skin and Soft Tissue Infection (UTI and pneumonia account for over half of all inpatient antibiotic use) JAMA. 2014; 312(14):
3 Key Topics to Cover Is CXR the Gold Standard? Pneumonia Diagnosis: CXR / Etiologies / Procalcitonin Antibiotics Steroids Healthcare-Associated Pneumonia Which pneumonia patients are at risk for resistant organisms? French study of 320 patients with suspected CAP Excluded very severe cases (ICU, CRB65 >3) Performed CXR in all Asked ED docs to assess: Probability of CAP Antibiotic plan Site of care decisions Perform Chest CT! Ask docs again Claessens YE, AJRCCM Is CXR the Gold Standard? 120 pts with CXR : 30% with CT infiltrates 190 pts with + CXR: 30% with NO CT infiltrates ED docs modified probability of CAP in 60% 80% in line with adjudicated diagnosis Modify treatment, drug or site of care : 61%! CT for Everyone!? Caveats Antibiotics after CT: 15% stopped, 45% started CT differed often with clinical / CXR disconnect CXR negative but high WBC, CRP, age, crackles CXR positive but no concerning findings Alternate diagnoses: CHF, COPD Claessens YE, AJRCCM Takehome: CXR is one part of the assessment and is imperfect 3
4 Case #1 A 64 yo woman with CHF is admitted with 2 days of fever, nonproductive cough, and shortness of breath. She has been on levofloxacin for 24 hrs per PCP. T 38.8, BP 110/75, HR 90, sats 89% RA. WBC 11 k. CXR shows a patchy RLL infiltrate. She is started on Ceftriaxone / Azithro in the ED and admitted to you. Her respiratory panel is positive for adenovirus and her serum procalcitonin (x2) is 0.05mcg / L. Now what?: 1) Wait for blood and sputum cultures before deciding 2) Stop antibiotics 3) Continue antibiotics for possible bacterial co-infection 4) Stop antibiotics and start Lasix for CHF exacerbation Traditional thinking: CAP Etiologies S. Pneumoniae H. Influenzae Moraxella catarrhalis Klebsiella Atypicals (legionella, Mycoplasma, C. pneumoniae) S. Aureus CAP Etiologies CDC study in Chicago / Nashville (5 hospitals) All hospitalized adults with + CXR (>2000) Screened 18 hrs/ d, 7 d / week! week f/u Control group without CAP in Nashville 80% Ward, 20% ICU Jain S. NEJM
5 Procalcitonin Procalcitonin: The Algorithm Microbial toxins and bacterial-specific proinflammatory mediators stimulate release Levels are higher with bacterial infections vs. other Rapid rise / fall correlates with clinical response Correlates with severity of illness / prognosis Not affected by steroids Rapid testing available CHEST 2012 Procalcitonin and Antibiotic Use RCT/Year Patients with Respiratory Infection Setting Christ-Crain, ED Christ-Crain, ED/Inpt. Stolz, ED/Inpt. Briel, Multicenter Nobre, ICU Kristoffeger, ED/Inpt Schuetz, Multicenter Stolz, Multicenter, ICU Long, ED Burkhardt, ICU Bouadma, ED Long, ED Antibiotic Use Procalcitonin and Outcomes 14 Trials, 4221 Patients with Respiratory Infections OR=0.94 ( ) 5.7% 6.3% Mortality OR=0.82 ( ) 19% 22% Treatment Failure PCT Control CID 2012 Cochrane
6 Procalcitonin: Caution Warranted Procalcitonin: Use in Practice 260 CAP pts: Extensive diagnostic testing (blood, sputum, urine antigens, PCT, PCR for viral) 23% bacterial, 16% viral (+/- bacterial), 46%? Bacterial: 23% with PCT < 0.1 mcg / L (many PSI IV) Viral: 23% with PCT > 0.25 mcg / L A low PCT cannot RELIABLY exclude serious bacterial infection Musher, et al. J. Infection ,000 COPD patients; 5% with PCT testing Weak association with fewer abx starts No association with duration of therapy Lindenauer, In Press, % did not get more than 1 PCT test Lindenauer, In Press, 2016 Vaughn, Submitted, 2016 Procalcitonin: Bottom Line Key Topics to Cover It is another less than perfect, but potentially useful diagnostic test Should not be sole variable used to decide whether to use antibiotics or not Most useful when on the fence re giving / stopping antibiotics e.g., infiltrate, positive viral panel AND low PCT It can reduce antimicrobial use if protocols for deescalation are followed Pneumonia Diagnosis: CXR / Etiologies / Procalcitonin Antibiotics Steroids Healthcare-Associated Pneumonia Which pneumonia patients are at risk for resistant organisms? 6
7 Key Issues in Antibiotic Management Macrolides and Outcomes Meta-analysis; 23 studies with138,000 patients Are macrolides (atypical coverage) necessary? What regimens are effective for aspiration pneumonia? What duration of treatment is ideal? Macrolides vs. Nonmacrolides Mortality: RR=0.78 ( ) Asadi, CID, 2012 Macrolides: Immunomodulatory Properties? Antibiotic Therapy IDSA / ATS 2007 Guidelines + Modifications b-lactam* + macrolide (or doxycycline) (*Ceftriaxone, Cefotaxime, Amp / Sul, Ertapenem, Ceftaroline) Or, Respiratory fluoroquinolone Corrales-Medina, Jo Infection, 2011 ICU: ß-lactam+macrolide Or ß-lactam+fluoroquinolone Anti-pseudomonal (many options) or CA-MRSA Rx (Vanco or Linezolid) if risk factors: independent of ICU status 7
8 Macrolides and Outcomes Meta-analysis; 23 studies with138,000 patients Macrolides and Pneumonia RCT: Beta Lactam + Macrolide vs. Beta Lactam Beta-lactam + macro vs. Fluoroquinolone Mortality RR = 1.17 ( ) Macrolide vs. Nonmacrolide (RCTs only) Mortality RR = 1.13 RR=1 ( ) Asadi, CID, 2012 RCT of 580 CAP pts; 6 Swiss hospitals Excluded: Severe Pneumonia, HCAP risk factors Legionella urine antigen performed in all Day7 Stability: HR < 100, SBP > 90, T < 38, RR < 24, Oxygen Sat > 90% RA by day 7 Macrolide: 67% No Macrolide: 59% Garin, et al. JAMA IM, 2014 Macrolides and Pneumonia RCT: Beta Lactam + Macrolide vs. Beta Lactam Hazard Ratio for Instability Atypical pathogens 0.33 ( ) PSI Class IV 0.81 ( ) No atypical pathogens 0.99 ( ) PSI Class I-III 1.06 ( ) (No diff at 90 days: mortality, ICU admits, LOS, complications, recurrence) Garin, et al. JAMA IM, 2014 Macrolides and Pneumonia Pragmatic, Cluster, Randomized,Non-Inferiority Trial Beta-lactam Beta-lactam + macro Fluoro Patients Adherence 93% 88% 93% 90 d Mort. 9% 11% 8.8% Days to oral LOS Beta-lactam monotherapy: Non-inferior! (for non-icu patients without legionella) Postma DF, et al. NEJM,
9 Azithromycin: The Downside Excess CV mortality during treatment NEJM 2012 Based on large registries; due to QT prolongation? 1 per 5000 courses: high CV risk patients Fluoroquinolones: The Downside Very broad spectrum drugs Broad GNR coverage Declining activity against Pseudomonas, E. Coli Increasing resistance (S. Pneumo, others) Adverse drug events C. difficile Adverse drug events FDA warnings against use in uncomplicated infections Tendon rupture, neuropathy / CNS effects, etc. A major driver of C. difficile Risk for C. Difficile High Risk Clindamycin Fluoroquinolones Cephalosporins / Carbepenems Low(er) Risk Penicillins, Macrolides, TMP/SMX No risk Tetracyclines Clearance of Colonization? Brown, AAC, 2013 Beta lactam / lactamase, metronidazole Dubberke, AAC, 2015 Ceftriaxone + Doxycycline? Does Doxycycline Protect against C. difficile? (Doernberg, et. al. CID, 2012) Observational, single center study Ceftriaxone + doxy vs. ceftriaxone +(levo or azithro) HR for C. diff = % lower rate of C. difficile for each day of doxy Doxycycline Has some activity against C.difficile Inhibits protein synthesis (and C. diff toxin production) Absorbed in the upper GI tract (less colonic delivery) 9
10 Antibiotics for Pneumonia: Options Beta lactam + macrolide vs. beta lactam alone More benefit demonstrated in sicker patients May not be necessary in some ward patients (Assuming they do not have legionella) Fluoroquinolones vs. beta lactam + macrolide Ward patients: comparable outcomes to beta + macrolide beta + macrolide favored for sicker patients Important downsides exist Beta-lactam/lactamase+macrolide; beta-lacta + doxy Potentially beneficial if C. difficile is a local problem Less outcome data Case # 2 A 78 y.o. woman is admitted from assisted living with 2 days of somnolence / confusion and 1 day of fever, cough, and sputum production. She was recently started on hydrocodone for acute low back pain. T 38.5, HR 115, BP , sat 89%. Her CXR shows a RLL infiltrate, concerning for aspiration. In addition to stopping her narcotics, the most appropriate treatment is: 1) Supportive care only 2) Ceftriaxone + Azithromycin 3) Ceftriaxone + Azithromycin + Clindamycin 4) Clindamycin Aspiration Pneumonia 15% of CAP hospitalizations called aspiration pneumonia, but All pneumonia is essentially aspiration pneumonia 50% of healthy adults aspirate during sleep Are the elderly unique? Silent Aspiration Elderly with CAP 70% Elderly w/o CAP 10% Pneumonia if reduced host defenses / high bacterial load Marik, Curr Op Pulm Med Aspiration Pneumonia A Distinct Clinical Phenotype? At risk : Chronic neurologic / swallowing disorders Altered consciousness / alcohol or drugs Vomiting / witnessed choking Gravity dependent radiographic changes Older, more co-morbidity Higher 1 year mortality / higher recurrence Adds to mortality in CAP and HCAP Taylor, Am J Med Komiya, Respirology
11 Aspiration Pneumonia: Anaerobes El Sohl, et al. Am J Crit Care elderly NH patient with severe aspiration Quantitative bronchial sampling 67 pathogens isolated 50% GNRs 15% staph 15% anaerobes (over half also had GNR); low virulence orgs Poor functional status associated with anaerobes 85% of patients with an anaerobe isolated improved on regimens without dedicated anaerobic coverage Aspiration Pneumonia: Anaerobes When to cover anaerobes Indolent symptoms Severe periodontal disease Putrid sputum Necrotizing / cavitary lesions / post-obstructive Large effusions (is it an empyema?) Elderly + poor functional status? Alcoholics Aspiration Pneum(onitis vs. onia) Aspiration Pneumonia CAP Pneumonitis? Time to Symptom Resolution Jaoude, Emerg Med, 2012 Aspiration Pneumonia Time to Clinical Stability < 2 days > 2 days Patients Nursing home 67% 64% ICU transfer 0 23%* LOS (d) 4 6.5* 30 d mortality 9% 37%* β-lactam+macro 73% 70% Added clinda 2% 6% Authors propose stopping antibiotics in aspiration patients whose symptoms resolve in <48 hrs * = significant difference Jaoude, Emerg Med,
12 Aspiration Pneumonia Treatment Most do well with routine CAP treatment Risk stratify for anaerobes If concerned: Ceftriaxone / Levo are active against most oral anaerobes (but may miss B. Fragilis, some clostridia) Ceftriaxone + Metronidazole: all anaerobes Ceftriaxone + Clindamycin: all anaerobes, but also gets your pt C. Difficile Treatment Duration: 5 Days 5 Days Rx and Stop if: T < 37.8 for 48 hrs and: No More than 1 of: SBP < 90 HR > 100 RR > 24 Sat < 90% Control Physician discretion Uranga, JAMA IM 2016 Treatment Duration: 5 Days 5 Days and Stop Control Patients Day Success 92% 89% Abx Days (Median) Day Readmission 1.4% 6.6% 70% of the intervention group received 5 days of treatment Uranga, JAMA IM % Appropriate Duration: How well do we do? 10 Michigan Hospitals 1400 Pneumonia Patients 53.4% 50% 40% 30.8% 30% 20% 15.9% 10% 0% Appropriate Duration Excess Duration Excluded from logic 12
13 The First 5 Days Steroids for Pneumonia Siemieniuk R, et. al. Ann Intern Med RCTS with > 2000 pts Outcome Risk Ratio Absolute Effect NNT Mortality 0.67 ( ) 3% fewer 33 (Severe CAP) 0.39 ( ) Need MV 0.45 ( ) 5% fewer 20 ARDS 0.24 ( ) 6.2% fewer 16 Ann Intern Med, 1964 LOS(d) -2.9 ( ) 1 d shorter Stability(d) -1.2 ( ) 1.2 d sooner Hyperglyc 1.5 ( ) 3.5% more 29 Steroids for Pneumonia ISSUES Mortality most affected in severe CAP Driven by one small study stopped early Variable definitions of severe Multiple steroid doses; from 1 dose to 10 days Excluded patients at risk for steroid adverse effects h/o GI bleed, immune suppression, etc. Key Topics to Cover Pneumonia Update Diagnosis: CXR / Etiologies / Procalcitonin Macrolides for everyone: necessary and safe? Steroids for pneumonia Healthcare-Associated Pneumonia Which pneumonia patients are at risk for resistant organisms? Hyperglycemia is associated with higher mortality? Await Ongoing Trials 13
14 Healthcare Associated Pneumonia IDSA / ATS Guidelines: Am J Resp Crit Care 2005 Home Therapy IV Wound Care Nursing care through health agency Hospital or Dialysis Clinic in past 30 days for Dialysis / Any IV therapy Hospitalized 2 days in past 90? days Nursing Home or Long-Term Care Facility At Risk for Multidrug-Resistant Organisms (MDROs) Vanco: 16% to 31% Pip-Tazo: 16% to 27% Jones, BE. CID, 2015 MRSA: 2.5% to 2% Pseudomonas: 1.9% to 2% Pseudomonal Coverage for Pneumonia 50% 10 Michigan Hospitals 1400 Pneumonia Patients 45% 2.1% 40% 35% 30% 25% 20% 15% 10% 1.0% 21.6% 22.6% 0.6% 44.4% 46.5% 0.0% Positive Pseudomonas No Pseudomonas Jones, BE. CID, % 0% 14.0% 10.9% 11.5% All CAP HCAP PNA? 14
15 HCAP: Diagnostic Performance From : Sensitivity increased (a little) Specificity decreased ( a lot) Diagnostic odds no better Meaning? The percentage of patients covered for MRSA and Pseudomonas without MRSA / Pseudomonas doubled 1/3 of patients with positive cultures did not get coverage Our current approach really sucks Predicting Drug Resistant Organisms An Evolving Story HCAP risk factors not all associated with MDROs Prior MRSA / pseudomonal infection : Important! Treatment for MDROs and Outcomes Severity adjusted outcomes not worse with HCAP Risk stratification for MDROs necessary Low risk: outcomes good with CAP treatment High risk: outcome better? with broad spectrum rx JHM, JGIM: 2012 Predicting Drug Resistant Organisms Risk Scores: %Accuracy ATS HCAP Criteria 69% DRIP 81% Schreiber 68% Shorr 56% Niederman 65% Shindo 67% Aliberti 66% Park 73% (Tested in culture positive patients, NPV >>> PPV) Webb, AAC Predicting MRSA and Pseudomonas MRSA More Likely Prior MRSA IVDU Dialysis High MRSA prevalence Prior hospital Less Likely No nasal colonization Pseudomonas More Likely Prior pseudomonas COPD Bronchiectasis Prior fluroquinolones Inhaled steroids Prior hospital Metersky, Resp 2016 Waterer, Resp
16 Putting it All Together Strong Risk Factors for Resistant Organisms Prior Hospitalization in past 90 days / prior broad abx LTAC / SNF if prior antibiotics, poor functional status Critically Ill patients Prior MRSA / Pseudomonas Bronchiectasis / COPD (recurrent abx / chronic steroids) Weaker, Unclear Nursing home (alone) Dialysis (may be MRSA risk) Wound Care / Home Health / Feeding tubes / PPI/ H2 Too heterogeneous (but important) Immunosuppressed Higher Illness Severity Lower Illness Severity A General Approach Evaluate MDRO Risk Factors Quantity Risk If Broad Spectrum R x Blood/Sputum CX De-escalate if negative at day treatment is sufficient for most High MDRO Prevalence / Prior MDRO Low MDRO Prevalence Legend: Threshold for broad spectrum Rx Conclusions CXR / Etiologies / PCT CXR is imperfect and most CAP is viral Following PCT protocols will help reduce abx overuse Macrolides Data still supports use in sicker pts Ward patients: benefit unclear? if no legionella Steroids May hold some promise Need further study to identify a target population, dosing Patients at risk for resistant organisms Risk stratify and target broad spectrum treatment De-escalate if cx negative; treat for 1 week THANK YOU! QUESTIONS? 16
17 De-escalation: HCAP Oral Antibiotic Options Augmentin Respiratory Fluoroquinolone (Levofloxacin, Moxifloxacin) Oral 3 rd generation cephalosporin 17
Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases
Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses
More informationIMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)
IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,
More informationObjectives 4/26/2017. Co-Investigators Sadie Giuliani, PharmD, BCPS Claude Tonnerre, MD Jayme Hartzell, PharmD, MS, BCPS
IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,
More informationAntimicrobial Stewardship in Ambulatory Care
Antimicrobial Stewardship in Ambulatory Care Nila Suntharam, M.D. May 5, 2017 Dr. Suntharam indicated no potential conflict of interest to this presentation. She does not intend to discuss any unapproved/investigative
More informationOptimizing Antibiotic Stewardship in the ED
Optimizing Antibiotic Stewardship in the ED Michael Pulia, MD MS FAAEM FACEP Director, UW EM Antibiotic Stewardship Research Program Chair, AAEM Antimicrobial Stewardship Task Force @DrMichaelPulia Learning
More informationESISTONO LE HCAP? Francesco Blasi. Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano
ESISTONO LE HCAP? Francesco Blasi Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano Community-acquired pneumonia (CAP): Management issues
More information10/13/14. Low: not well absorbed. Good: [blood and tissue] < than if given IV. High: > 90% absorption orally
Low: not well absorbed PO agent not for serious infection nitrofurantoin Good: [blood and tissue] < than if given IV [Therapeutic] in excess of [effective] eg. cephalexin High: > 90% absorption orally
More informationPneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center
Pneumonia considerations 2017 Galia Rahav Infectious diseases unit Sheba medical center Sir William Osler (1849 1919) "Father of modern medicine Pneumonia: The old man's friend The captain of the men of
More informationBai-Yi Chen MD. FCCP
Treatment strategies for hospitalized versus nonhospitalized CAP patients: Asian perspective Bai-Yi Chen MD. FCCP Professor of Medicine Division of Infectious Disease, Infection Control Team The First
More informationCommunity-Acquired Pneumonia Current & Future State
Community-Acquired Pneumonia Current & Future State Brad Sharpe, M.D. Professor of Clinical Medicine Department of Medicine UCSF sharpeb@medicine.ucsf.edu I have no relevant financial relationships to
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Pneumonia Community Acquired Pneumonia 1) Is it pneumonia? ie new symptoms and signs of
More informationAntimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS
Antimicrobial Stewardship in the Long Term Care and Outpatient Settings Carlos Reyes Sacin, MD, AAHIVS Disclosure Speaker and consultant in HIV medicine for Gilead and Jansen Pharmaceuticals Objectives
More informationOptimize Durations of Antimicrobial Therapy
Optimize Durations of Antimicrobial Therapy Evidence & Application Jill Cowper, Pharm.D. Division Infectious Diseases Pharmacist Parallon Supply Chain Solutions Richmond, VA P: 607 221 5101 jill.butterfield@parallon.com
More informationCommunity Acquired Pneumonia. Epidemiology: Acute Lower Respiratory Tract Infections. Community Acquired Pneumonia (CAP) Outline
Community Acquired Pneumonia (CAP) Outline Lisa G. Winston, MD University of California, San Francisco Zuckerberg San Francisco General Epidemiology Diagnosis Microbiology Risk stratification Treatment
More informationCommunity-acquired pneumonia: Time to place a CAP on length of treatment?
LOGIN TO LEARN: An Engaging and Interactive Journal Club for Pharmacists and Students Community-acquired pneumonia: Time to place a CAP on length of treatment? Jennifer Ball, PharmD Learning Objectives
More information11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose
Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationAntibiotic Abyss. Discussion Points. MRSA Treatment Guidelines
Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California
More informationAntibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco
Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance
More informationRational management of community acquired infections
Rational management of community acquired infections Dr Tanu Singhal MD, MSc Consultant Pediatrics and Infectious Disease Kokilaben Dhirubhai Ambani Hospital, Mumbai Why is rational management needed?
More informationInfectious Disease Update 2017
Infectious Disease Update 2017 Greg Moran, MD, FACEP, FIDSA Professor of Clinical Emergency Medicine Geffen School of Medicine at UCLA Dept. of Emergency Medicine and Division of Infectious Diseases Olive
More informationNewsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017
Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Fluoroquinolones Newsflash: Fluoroquinolones Don t
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Community Acquired 1) Is it pneumonia? ie new symptoms and signs of a lower respiratory
More information3/23/2017. Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc. Kathryn G. Smith: Nothing to disclose
Kathryn G. Smith, PharmD PGY1 Pharmacy Resident Via Christi Hospitals Wichita, Inc Kathryn G. Smith: Nothing to disclose Describe the new updates and rationale for them Relay safety concerns with use of
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationMethicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship
Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship Natalie R. Tucker, PharmD Antimicrobial Stewardship Pharmacist Tyson E. Dietrich, PharmD PGY2 Infectious Diseases
More informationAntibiotic Updates: Part I
Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationAZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES
AZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES Update in Medicine and Primary Care Whitney R. Buckel, PharmD, BCPS-AQ ID System Antimicrobial Stewardship Pharmacist Manager OBJECTIVES 1. List three antibiotics
More informationInfectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles
Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,
More informationTreatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days
Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of
More informationLet me clear my throat: empiric antibiotics in
Let me clear my throat: empiric antibiotics in respiratory tract infections Alexander John Langley, MD MS MPH Goals of this talk Overuse of antibiotics is a major issue, as a result many specialist medical
More information10/26/2015. Year in Review Brad Sharpe, MD UCSF Division of Hospital Medicine VS. Update in Hospital Medicine
Year in Review 2015 Brad Sharpe, MD UCSF Division of Hospital Medicine VS. 1 2015 Updated literature Sept 2014 Sept 2015 Process: CME collaborative review of journals Including ACP J. Club, J. Watch, etc.
More informationHigh Risk Emergency Medicine. Antibiotic Pitfalls
High Risk Emergency Medicine Antibiotic Pitfalls David, MD MS Assistant Professor Department of Emergency Medicine University of California, San Francisco I. Antibiotic Resistance Development of resistance
More informationAntibiotic stewardship in long term care
Antibiotic stewardship in long term care Shira Doron, MD Associate Professor of Medicine Division of Geographic Medicine and Infectious Diseases Tufts Medical Center Boston, MA Consultant to Massachusetts
More informationPneumonia. Community Acquired Pneumonia (CAP): definition. At least 2 new symptoms
Pneumonia Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital Community Acquired Pneumonia (CAP): definition At least 2 new symptoms Fever or hypothermia Cough Rigors
More informationCommunity-Acquired Pneumonia: A Re-CAP
Community-Acquired Pneumonia: A Re-CAP Meghan Griebel, PharmD Iowa City VA Health Care System Disclosure Meghan Griebel does not have any actual or potential conflicts of interest to disclose. 2 Goal At
More informationDuration of antibiotic therapy:
Duration of antibiotic therapy: How low can you go? Thomas Holland, MD Hilton Head, SC July 2017 Disclosures Consulting: The Medicines Company, Basilea Pharmaceutica Adjudication committee: Achaogen Grant
More informationProcalcitonin to Predict Septic Shock & Guide Antibiotic Therapy
Procalcitonin to Predict Septic Shock & Guide Antibiotic Therapy William T. McGee, M.D. MHA, FCCM, FCCP Critical Care Medicine Associate Professor of Medicine and Surgery University of Massachusetts 759
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More informationAntimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD
Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an
More informationCLINICAL PROTOCOL FOR COMMUNITY ACQUIRED PNEUMONIA. SCOPE: Western Australia. CORB score equal or above 1. All criteria must be met:
CLINICAL PROTOCOL F COMMUNITY ACQUIRED PNEUMONIA SCOPE: Western Australia All criteria must be met: Inclusion Criteria Exclusion Criteria CB score equal or above 1. Mild/moderate pneumonia confirmed by
More informationAntibiotic Stewardship in the LTC Setting
Antibiotic Stewardship in the LTC Setting Joe Litsey, Director of Consulting Services Pharm.D., Board Certified Geriatric Pharmacist Thrifty White Pharmacy Objectives Describe the Antibiotic Stewardship
More informationMeasure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationCommunity-Acquired Pneumonia. Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital. Nothing to disclose.
Community-Acquired Pneumonia Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital Nothing to disclose. Community-Acquired Pneumonia Talk will focus on adults Guideline
More informationDisclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials
Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site
More informationInitial Management of Infections in the Era of Enhanced Antimicrobial Resistance
Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Robert C Welliver Sr, MD Hobbs-Recknagel Endowed Chair in Pediatrics Chief, Pediatric infectious Diseases Children s Hospital
More informationSuitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP)
STUDY PROTOCOL Suitability of Antibiotic Treatment for CAP (CAPTIME) Purpose The duration of antibiotic treatment in community acquired pneumonia (CAP) lasts about 9 10 days, and is determined empirically.
More informationManagement of Hospital-acquired Pneumonia
Management of Hospital-acquired Pneumonia Adel Alothman, MB, FRCPC, FACP Asst. Professor, COM, KSAU-HS Head, Infectious Diseases, Department of Medicine King Abdulaziz Medical City Riyadh Saudi Arabia
More informationECHO: Management of URIs. Charles Krasner, M.D. Sierra NV Veterans Affairs Hospital University of NV, Reno School of Medicine October 16, 2018
ECHO: Management of URIs Charles Krasner, M.D. Sierra NV Veterans Affairs Hospital University of NV, Reno School of Medicine October 16, 2018 Infectious causes of URIs change over time Most ARIs are viral
More informationApproach to pediatric Antibiotics
Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus
More informationAntimicrobial Stewardship
Antimicrobial Stewardship Background Why Antimicrobial Stewardship 30-50% of antibiotic use in hospitals are unnecessary or inappropriate Appropriate antimicrobial use is a medication-safety and patient-safety
More informationAntimicrobial Stewardship
Antimicrobial Stewardship Reducing Antibiotic use in Hospitalized Patients with Pneumonia Brittany Marshall, Pharm.D.,BCPS MultiCare Good Samaritan Hospital brittany.marshall@multicare.org Disclosure Statement
More informationFor analyst certification and disclosures please see page 7
Physician Survey Survey of Healthcare Professionals on Community-Acquired Bacterial Pneumonia We conducted a survey on prescribing habits for community-acquired bacterial pneumonia (CABP) in order to better
More informationClostridium Difficile Primer: Disease, Risk, & Mitigation
Clostridium Difficile Primer: Disease, Risk, & Mitigation KALVIN YU, M.D. CHIEF INTEGRATION OFFICER, SCPMG/SCAL KAISER PERMANENTE ASSOCIATE PROFESSOR INFECTIOUS DISEASE, COLLEGE OF GLOBAL PUBLIC HEALTH,
More informationChallenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S.
Challenges and opportunities for rapidly advancing reporting and improving inpatient antibiotic use in the U.S. Overview of benchmarking Antibiotic Use Scott Fridkin, MD, Senior Advisor for Antimicrobial
More informationAntibiotic Stewardship Program (ASP) CHRISTUS SETX
Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:
More information11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1
Disclosures Selecting Antimicrobials for Common Infections in Children FMR-Contemporary Pediatrics 11/2016 Sean McTigue, MD Assistant Professor of Pediatrics, Pediatric Infectious Diseases Medical Director
More informationHost, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus
Host, Syndrome, Bug, Drug: Introducing 2 Frameworks to Approach Infectious Diseases Cases with an Antimicrobial Stewardship Focus Montana ACP Meeting 2018 September 8, 2018 Staci Lee, MD, MEHP Billings
More informationANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES
ANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES ANTIMICROBIAL STEWARDSHIP COLLABORATIVE COLORADO HOSPITAL ASSOCIATION MARCH 23, 2016 Bridget Olson, RPh Infectious Disease Pharmacist, Sharp Coronado
More informationCommunity-Acquired Pneumonia. Community-Acquired Pneumonia. Community Acquired Pneumonia (CAP): definition
Community-Acquired Pneumonia Lisa G. Winston, MD University of California, San Francisco San Francisco General Hospital Community-Acquired Pneumonia Talk will focus on adults Guideline for healthy infants
More informationGeneral Approach to Infectious Diseases
General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor
More informationAdvanced Practice Education Associates. Antibiotics
Advanced Practice Education Associates Antibiotics Overview Difference between Gram Positive(+), Gram Negative(-) organisms Beta lactam ring, allergies Antimicrobial Spectra of Antibiotic Classes 78 Copyright
More informationPneumonia. Jodi Grandominico, MD
Pneumonia Jodi Grandominico, MD Assistant Professor of Clinical Medicine Department of Internal Medicine Division of General Medicine and Geriatrics The Ohio State University Wexner Medical Center Pneumonia
More informationControl emergence of drug-resistant. Reduce costs
...PRESENTATIONS... Guidelines for the Management of Community-Acquired Pneumonia Richard E. Chaisson, MD Presentation Summary Guidelines for the treatment of community-acquired pneumonia (CAP) have been
More informationDuke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients
Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity
More informationTreatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani
Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani 30-1-2018 1 Objectives of the lecture At the end of lecture, the students should be able to understand the following:
More informationNEW ATS/IDSA VAP-HAP GUIDELINES
NEW ATS/IDSA VAP-HAP GUIDELINES MARK L. METERSKY, MD PROFESSOR OF MEDICINE UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE FARMINGTON, CT Mark Metersky, MD, FCCP, FACP is a Professor of Medicine at the University
More information8/17/2016 ABOUT US REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM
Mary Moore, MS CIC MT (ASCP) Infection Prevention Coordinator Great River Medical Center, West Burlington REDUCTION OF CLOSTRIDIUM DIFFICILE THROUGH THE USE OF AN ANTIMICROBIAL STEWARDSHIP PROGRAM ABOUT
More informationNecrotizing Soft Tissue Infections: Emerging Bacterial Resistance
Necrotizing Soft Tissue Infections: Emerging Bacterial Resistance Eileen M. Bulger, MD Professor of Surgery Harborview Medical Center University of Washington Objectives Review definition & diagnostic
More informationCommunity-Associated C. difficile Infection: Think Outside the Hospital. Maria Bye, MPH Epidemiologist May 1, 2018
Community-Associated C. difficile Infection: Think Outside the Hospital Maria Bye, MPH Epidemiologist Maria.Bye@state.mn.us 651-201-4085 May 1, 2018 Clostridium difficile Clostridium difficile Clostridium
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationDisclosures. Nothing Medically I own FiPhysician LLC, a financial planning and investment company (FiPhysician.com)
"How to work around (with) administration to build an Antimicrobial Stewardship Program AND how to get dumb (oops reluctant) doctors to do the right thing" David Graham, MD Disclosures Nothing Medically
More informationWhat is pneumonia? Infection of the lung parenchyma Causative agents include bacteria, viruses, fungi, protozoa.
Pneumonia What is pneumonia? Infection of the lung parenchyma Causative agents include bacteria, viruses, fungi, protozoa www.netmedicine.com/xray/xr.htm Definition acute infectious disease, etiology usually
More informationPNEUMONIA PRACTICE GUIDELINES
PNEUMONIA PRACTICE GUIDELINES WHERE ARE WE NOW STEPHEN SOKALSKI DO FACOI ADVOCATE CHRIST MEDICAL CENTER PNEUMONIA GUIDELINES THEY SEEMED LIKE A GOOD IDEA AT THE TIME. ARE THEY STILL? INDICATORS INCLUDED
More informationVolume 1; Number 7 November 2007
Volume 1; Number 7 November 2007 CONTENTS Page 1 Page 3 Guidance on the Use of Antibacterial Drugs in Lincolnshire Primary Care: Winter 2007/8 NICE Clinical Guideline 54: Urinary Tract Infection in Children
More informationAntimicrobial Update Stewardship in Primary Care. Clare Colligan Antimicrobial Pharmacist NHS Forth Valley
Antimicrobial Update Stewardship in Primary Care Clare Colligan Antimicrobial Pharmacist NHS Forth Valley Setting the Scene! Consequences of Antibiotic Use? Resistance For an individual patient with
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 3.2a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Organization Set Measure ID#
More informationIDSA GUIDELINES COMMUNITY ACQUIRED PNEUMONIA
page 1 / 5 page 2 / 5 idsa guidelines community acquired pdf IDSA/ATS Guidelines for CAP in Adults CID 2007:44 (Suppl 2) S29 such as blood and sputum cultures. Conversely, these cultures may have a major
More informationANTIMICROBIAL STEWARDSHIP: THE ROLE OF THE CLINICIAN SAM GUREVITZ PHARM D, CGP BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCES
ANTIMICROBIAL STEWARDSHIP: THE ROLE OF THE CLINICIAN SAM GUREVITZ PHARM D, CGP BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCES 1 Crisis: Antibiotic Resistance Success Strategy 2 OBJECTIVES Discuss
More informationAntibiotic treatment in the ICU 1. ICU Fellowship Training Radboudumc
Antibiotic treatment in the ICU 1 ICU Fellowship Training Radboudumc Main issues Delayed identification of microorganisms Impact of critical illness on Pk/Pd High prevalence of antibiotic resistant strains
More informationAntibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Antibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease Sung Kyu Kim, M.D.Young Sam Kim, M.D. Department of Internal Medicine Yonsei University College of Medicine,
More informationAn Approach to Appropriate Antibiotic Prescribing in Outpatient and LTC Settings?
An Approach to Appropriate Antibiotic Prescribing in Outpatient and LTC Settings? Dr. Andrew Morris Antimicrobial Stewardship ProgramMt. Sinai Hospital University Health Network amorris@mtsinai.on.ca andrew.morris@uhn.ca
More informationAntibiotics in the trenches: An ER Doc s Perspective
Antibiotics in the trenches: An ER Doc s Perspective Peter Currie, MD Medical Director for Quality Emergency Physicians Professional Association (EPPA) Agenda Emergency Medicine Specific Disease Processes
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: CMS Voluntary Only
Last Updated: Version 4.4a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Collected For: CMS Voluntary
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More informationAntimicrobial Use Toolkit Webinar M A R C H 1 3,
Antimicrobial Use Toolkit Webinar M A R C H 1 3, 2 0 1 8 Welcome & Housekeeping Thank you for attending! HMS data abstractors Administrators QI staff Pharmacists Hospitalists ID physicians Individuals
More informationAntibiotic Stewardship in LTC What does this mean?
Antibiotic Stewardship in LTC What does this mean? Kieran Moore FCFP,FRCPC, Diane Lu CCFP KFLA Public Health Disclosure The findings and conclusions represent those of the presenter and may not necessarily
More informationStaph Cases. Case #1
Staph Cases Lisa Winston University of California, San Francisco San Francisco General Hospital Case #1 A 60 y.o. man with well controlled HIV and DM presents to clinic with ten days of redness and swelling
More informationCollecting and Interpreting Stewardship Data: Breakout Session
Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline
More informationResponsible Antibiotic Use
Procalcitonin Levels to Promote Responsible Antibiotic Use Judy Neubrander, EdD, FNP-BC Western Carolina University School of Nursing Learning Objectives To understand the issues associated with the increase
More informationANTIBIOTIC STEWARDSHIP IN LONG TERM CARE
ANTIBIOTIC STEWARDSHIP IN LONG TERM CARE How consultant pharmacists can help their facilities by Kelli Musick-Hocker, Pharm D. Complete Pharmacy Consulting Kansas City Why is antibiotic stewardship in
More informationAntimicrobial de-escalation in the ICU
Antimicrobial de-escalation in the ICU A FOCUS ON EVIDENCE-BASED STRATEGIES Dave Leedahl, PharmD, BCPS-AQ ID, BCCCP Pharmacy Clinical Manager Sanford Health Fargo, ND, USA I have no conflicts of interest
More informationM5 MEQs 2016 Session 3: SOB 18/11/16
M5 MEQs 2016 Session 3: SOB 18/11/16 http://tinyurl.com/hn7qzt3 Question 1 Ms Tan is a 52 year old female with no past medical history. She comes to the emergency department presenting with a fever for
More information